Skip to main content
. 2019 Sep 17;3:100042. doi: 10.1016/j.jvacx.2019.100042

Table 1.

Genetic group distribution among nine study sites participating in the random sequencing of influenza virus positive specimens. I-MOVE/I-MOVE+ primary care multicenter case control study, Europe, influenza season 2016–17 and 2017–18.

Characterised viruses1 Clade/subclade DE
 ES
 FR
 HU
 IE
 NL
 PT
 RO
 SE
 Total
N % N % N % N % N % N % N % N % N % N %
2016–17 A(H3N2)
207
346
87
51
63
80
124
25
67
1050
A/HongKong/4801/2014-like 3C.2a 47 23 59 17 28 32 15 29 14 22 16 20 42 34 10 40 25 37 256 24
* 1 2 0 0 0 0 0 0 0 0 2 13 2 5 0 0 0 0 5 2
N121K+S144K+(N122D+262N) 3C.2a3 30 64 54 92 27 96 14 93 11 79 8 50 38 90 10 100 16 64 208 81
T131K+R142K+R261Q
 3C.2a2
 16
 34
 5
 8
 1
 4
 1
 7
 3
 21
 6
 38
 2
 5
 0
 0
 9
 36
 43
 17
A/Bolzano/7/2016-like2 3C.2a1 159 77 280 81 59 68 36 71 45 71 63 79 82 66 15 60 42 63 781 74
N171K 14 9 137 49 40 68 1 3 1 2 9 14 1 1 6 40 7 17 216 28
N171K+N121K+I140M – 32 20 58 21 7 12 2 5 6 13 14 22 6 7 7 47 8 19 140 18
N171K+N121K+K92R+H311Q 3C.2a1b 43 27 59 21 1 2 4 11 5 11 18 29 29 35 1 7 1 2 161 21
N171K+N121K+T135K 3C.2a1a 54 34 8 3 2 3 28 78 1 2 11 17 0 0 1 7 22 52 128 16
N171K+R142G
 –
 16
 10
 18
 6
 9
 15
 1
 3
 32
 71
 11
 17
 46
 56
 0
 0
 4
 10
 137
 18
A/Switzerland/9715293/2013-like
 3C.3a
 1
 0
 7
 2
 0
 0
 0
 0
 4
 6
 1
 1
 0
 0
 0
 0
 0
 0
 13
 1
Characterised viruses Clade/subclade DE
 ES
 FR
 HU
 IE
 NL
 PT
 RO3
 SE
 Total
N % N % N % N % N % N % N % N % N % N %
2017–18 A(H1N1)pdm09 43 10 64 – 13 31 22 13 9 205
A/Michigan/45/2015-like
 6B.1
 43
 100
 10
 100
 64
 100
13
 100
 31
 100
 22
 100
 13
 100
 9
 100
 205
 100
A(H3N2)
25
141
35
–
48
26
13
–
24
312
A/HongKong/4801/2014-like 3C.2a 23 92 44 31 25 71 – 41 85 18 69 7 54 – 15 63 173 55
* 0 0 0 0 0 0 – 0 0 0 0 0 0 – 0 0 0 0
N121K+S144K+(N122D+262N) 3C.2a3 2 9 0 0 1 4 – 3 7 0 0 0 0 – 0 0 6 3
T131K+R142K+R261Q
 3C.2a2
 21
 91
 44
 100
 24
 96
 –
38
 93
 18
 100
 7
 100
 –
15
 100
 167
 97
A/Singapore/INFIMH-16-0019/2016-like2 3C.2a1 2 8 97 69 8 23 – 6 13 8 0 6 46 – 7 29 134 43
N171K+N121K 0 0 0 0 0 0 – 0 0 0 0 0 0 – 0 0 0 0
N171K+N121K+I140M – 0 0 0 0 0 0 – 0 0 0 0 0 0 – 0 0 0 0
N171K+N121K+K92R+H311Q 3C.2a1b 1 50 96 99 8 100 – 6 100 8 100 6 100 – 7 100 132 99
N171K+N121K+T135K 3C.2a1a 1 50 1 1 0 0 – 0 0 0 0 0 0 – 0 0 2 1
N171K+R142G
 –
 0
 0
 0
 0
 0
 0
 –
0
 0
 0
 0
 0
 0
 –
0
 0
 0
 0
A/Switzerland/9715293/2013-like
 3C.3a
 0
 0
 0
 0
 2
 6
 –
1
 2
 0
 0
 0
 0
 0
2
 8
 5
 2
Total 2017–18 68 151 89 – 61 57 35 13 33 517
*

Viruses with no amino acid substitutions or substitutions outside of the A–E antigenic sites.

1

We use for both seasons the clade/subclade denomination created in mid-season in 2017-18 (report prepared by the Francis Crick Institute for the WHO annual consultation on the composition of influenza vaccine for the Northern Hemisphere 2018-2019). Therefore some clades/subclades circulating in 2016–17, but not in 2017–18, have no specific clade/subclade denomination. All amino acid substitutions shown for the A(H3N2) overarching clade 3C.2a viruses are relative to the vaccine virus A/HongKong/4801/2014.

2

A/Bolzano/7/2016 and A/Singapore/INFIMH-16-0019/2016 are two representative viruses of the same clade 3C.2a1, carrying the N171K substitution in the HA gene compared to the vaccine virus A/HongKong/4801/2014. In 2016–117, A/Bolzano/7/2016 was used as the representative virus and in 2017–118 A/Singapore/INFIMH-16-0019/2016 was used being representative for clade 3C.2a1 viruses carrying N121K in addition to N171K and chosen as vaccine strain for the 2018 Southern Hemisphere and 2018/2019 Northern Hemisphere vaccines.

3

Romania sequenced 7 A(H3N2) viruses, but they are excluded from the pooled analysis as they had fewer than 10 cases.